+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rhinovirus Infections - Pipeline Review, H2 2019

  • ID: 4866512
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 50 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Biological Mimetics Inc
  • Gilead Sciences Inc
  • Meissa Vaccines Inc
  • PrEP Biopharm Ltd
  • Sagimet Biosciences
  • MORE
Rhinovirus Infections - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Rhinovirus Infections - Pipeline Review, H2 2019, provides an overview of the Rhinovirus Infections (Infectious Disease) pipeline landscape.

Rhinoviruses are common cause of the common cold. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Rhinovirus Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Rhinovirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhinovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Rhinovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhinovirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rhinovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhinovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhinovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhinovirus Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhinovirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhinovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Apollo Therapeutics LLC
  • Biological Mimetics Inc
  • Gilead Sciences Inc
  • Meissa Vaccines Inc
  • PrEP Biopharm Ltd
  • Sagimet Biosciences
  • MORE
Introduction
Report Coverage
Rhinovirus Infections - Overview
Rhinovirus Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rhinovirus Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rhinovirus Infections - Companies Involved in Therapeutics Development
Apollo Therapeutics LLC
AstraZeneca Plc
Biological Mimetics Inc
Collaborations Pharmaceuticals Inc
Enyo Pharma SA
Gilead Sciences Inc
Haplogen GmbH
Meissa Vaccines Inc
Polyrizon Ltd
PrEP Biopharm Ltd
Romark Laboratories LC
Sagimet Biosciences
Secarna Pharmaceuticals GmbH & Co. KG
ST Pharm Co Ltd
Symmune Therapeutics LLC
Viravaxx AG
Rhinovirus Infections - Drug Profiles
Antisense Oligonucleotide for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNT-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Enterovirus Infections and Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Rhinovirus and Coxsackievirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
human rhinovirus (polyvalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBR-5340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polymer for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rhinovirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PLA2G16 for Rhinovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVB-3567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rhinovirus Infections - Dormant Projects
Rhinovirus Infections - Discontinued Products
Rhinovirus Infections - Product Development Milestones
Featured News & Press Releases
May 10, 2017: Meissa announces award of NIH SBIR grant to support development of multivalent human rhinovirus vaccine candidate
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Rhinovirus Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products by Stage and Target, H2 2019
Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
Table 8: Number of Products by Stage and Route of Administration, H2 2019
Table 9: Number of Products by Stage and Molecule Type, H2 2019
Table 10: Rhinovirus Infections - Pipeline by Apollo Therapeutics LLC, H2 2019
Table 11: Rhinovirus Infections - Pipeline by AstraZeneca Plc, H2 2019
Table 12: Rhinovirus Infections - Pipeline by Biological Mimetics Inc, H2 2019
Table 13: Rhinovirus Infections - Pipeline by Collaborations Pharmaceuticals Inc, H2 2019
Table 14: Rhinovirus Infections - Pipeline by Enyo Pharma SA, H2 2019
Table 15: Rhinovirus Infections - Pipeline by Gilead Sciences Inc, H2 2019
Table 16: Rhinovirus Infections - Pipeline by Haplogen GmbH, H2 2019
Table 17: Rhinovirus Infections - Pipeline by Meissa Vaccines Inc, H2 2019
Table 18: Rhinovirus Infections - Pipeline by Polyrizon Ltd, H2 2019
Table 19: Rhinovirus Infections - Pipeline by PrEP Biopharm Ltd, H2 2019
Table 20: Rhinovirus Infections - Pipeline by Romark Laboratories LC, H2 2019
Table 21: Rhinovirus Infections - Pipeline by Sagimet Biosciences, H2 2019
Table 22: Rhinovirus Infections - Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H2 2019
Table 23: Rhinovirus Infections - Pipeline by ST Pharm Co Ltd, H2 2019
Table 24: Rhinovirus Infections - Pipeline by Symmune Therapeutics LLC, H2 2019
Table 25: Rhinovirus Infections - Pipeline by Viravaxx AG, H2 2019
Table 26: Rhinovirus Infections - Dormant Projects, H2 2019
Table 27: Rhinovirus Infections - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Rhinovirus Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Apollo Therapeutics LLC
  • AstraZeneca Plc
  • Biological Mimetics Inc
  • Collaborations Pharmaceuticals Inc
  • Enyo Pharma SA
  • Gilead Sciences Inc
  • Haplogen GmbH
  • Meissa Vaccines Inc
  • Polyrizon Ltd
  • PrEP Biopharm Ltd
  • Romark Laboratories LC
  • Sagimet Biosciences
  • Secarna Pharmaceuticals GmbH & Co. KG
  • ST Pharm Co Ltd
  • Symmune Therapeutics LLC
  • Viravaxx AG
Note: Product cover images may vary from those shown
Adroll
adroll